Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term

Core Viewpoint - Zacks Premium provides various tools and resources to help investors make informed decisions and enhance their investment strategies Investment Tools and Features - Zacks Premium includes daily updates of the Zacks Rank and Zacks Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service also offers Zacks Style Scores, which are designed to assist investors in selecting stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores - The Zacks Style Scores rate stocks using an alphabetic system (A, B, C, D, F) based on value, growth, and momentum characteristics, with A being the highest rating [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - Evaluates a company's financial health and future growth potential by analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Targets stocks experiencing upward or downward trends in price or earnings, utilizing factors like one-week price change and monthly earnings estimate changes [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating based on value, growth, and momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to help investors build successful portfolios [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +23.64% since 1988, significantly outperforming the S&P 500 [7] Stock Selection Strategy - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B to maximize potential returns [9] - Stocks with lower ranks, even if they have high Style Scores, may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: Exact Sciences (EXAS) - Exact Sciences Corporation specializes in molecular diagnostics for early cancer detection, focusing on colorectal cancer screening, molecular residual disease testing, and multi-cancer screening [11] - EXAS holds a Zacks Rank of 3 (Hold) with a VGM Score of A and a Momentum Style Score of A, having seen a 12.3% increase in shares over the past four weeks [11][12] - Recent earnings estimates for fiscal 2025 have been revised upward, with the Zacks Consensus Estimate increasing by $0.20 to $0.36 per share, and the company has an average earnings surprise of +329.9% [12]